Search

Your search keyword '"Lederlin M"' showing total 334 results
Start Over Author "Lederlin M"
334 results on '"Lederlin M"'

2. Three artificial intelligence data challenges based on CT and MRI

Author

Lassau, N., Bousaid, I., Chouzenoux, E., Lamarque, J.P., Charmettant, B., Azoulay, M., Cotton, F., Khalil, A., Lucidarme, O., Pigneur, F., Benaceur, Y., Sadate, A., Lederlin, M., Laurent, F., Chassagnon, G., Ernst, O., Ferreti, G., Diascorn, Y., Brillet, P.Y., Creze, M., Cassagnes, L., Caramella, C., Loubet, A., Dallongeville, A., Abassebay, N., Ohana, M., Banaste, N., Cadi, M., Behr, J., Boussel, L., Fournier, L., Zins, M., Beregi, J.P., Luciani, A., Cotten, A., and Meder, J.F.

Published
2020
Full Text
View/download PDF

3. Artificial intelligence solution to classify pulmonary nodules on CT

Author

Blanc, D., Racine, V., Khalil, A., Deloche, M., Broyelle, J.-A., Hammouamri, I., Sinitambirivoutin, E., Fiammante, M., Verdier, E., Besson, T., Sadate, A., Lederlin, M., Laurent, F., Chassagnon, G., Ferretti, G., Diascorn, Y., Brillet, P.-Y., Cassagnes, Lucie, Caramella, C., Loubet, A., Abassebay, N., Cuingnet, P., Ohana, M., Behr, J., Ginzac, A., Veyssiere, H., Durando, X., Bousaïd, I., Lassau, N., and Brehant, J.

Published
2020
Full Text
View/download PDF

4. Imagerie de la pneumonie COVID-19

Author

Lodé, B., Jalaber, C., Orcel, T., Morcet-Delattre, T., Crespin, N., Voisin, S., Billard, F., Luzi, S., Lapotre, T., Lentz, P.-A., Revel, M.-P., and Lederlin, M.

Published
2020
Full Text
View/download PDF

16. Pulmonary manifestations induced by osimertinib

Author

Le Guen, Y, Lederlin, M, Triquet, L, Lesouhaitier, M, Le Tulzo, Y, Ricordel, C, CHU Pontchaillou [Rennes], Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and CRLCC Eugène Marquis (CRLCC)

Subjects
Pulmonary and Respiratory Medicine, 0303 health sciences, Pneumopathie interstitielle, Adverse drug reactions, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, respiratory tract diseases, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Effets secondaires indésirables des médicaments, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Cancer bronchique, Lung cancer, Osimertinib, Interstitial pneumonia, 030304 developmental biology
Abstract

National audience; INTRODUCTION: The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to osimertinib exposure have been reported, primarily in Japanese patients. They rarely occur in the Caucasian population. OBSERVATION: Herein we report two clinical cases of osimertinib-induced lung toxicities in patients diagnosed with advanced lung adenocarcinoma harboring an EGFR mutation. In the first case, interstitial pneumonia was asymptomatic and evolved favorably after osimertinib discontinuation. The second patient presented a more extensive form of lung injuries and despite systemic corticosteroid therapy, the evolution was fatal. CONCLUSION: Osimertinib-related lung toxicities remain exceptional. While most forms are mild, consideration of TKI treatment discontinuation may be necessitated. Introduction of another TKI or rechallenge with osimertinib might be considered along with corticosteroid therapy if necessary. Diffuse alveolar damage is a pejorative prognostic factor.

Published
2022
Full Text
View/download PDF

23. Ratio of Pulmonary Artery to Ascending Aortic Diameter Predicts Primary Graft Dysfunction After Cardiac Transplantation

Author

Bounader, K., primary, Affole, T., additional, Mariani, S., additional, Mauro, M. Di, additional, Mansour, A., additional, Aymami, M., additional, Charton, M., additional, Lelong, B., additional, Chabanne, C., additional, Nesseler, N., additional, Verhoye, J., additional, Lederlin, M., additional, and Flecher, E., additional

Published
2022
Full Text
View/download PDF

24. Target definition for cardiac radioablation of ventricular tachycardia: A multimodal workflow

Author

Rigal, L., Martins, R., Benali, K., Bellec, J., Lederlin, M., de Crevoisier, R., Simon, A., Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLCC Eugène Marquis (CRLCC), CHU Pontchaillou [Rennes], and Jonchère, Laurent

Subjects
[SDV.IB] Life Sciences [q-bio]/Bioengineering, [SDV.IB]Life Sciences [q-bio]/Bioengineering
Abstract

International audience; Meeting Abstract PO-1622

Published
2022

28. Combined assessment of septal scar and septal flash by cardiac magnetic resonance identifies responders to cardiac resynchronization therapy

Author

Kjellstad Larsen, C, primary, Duchenne, J, additional, Galli, E, additional, Aalen, JM, additional, Lederlin, M, additional, Bogaert, J, additional, Kongsgaard, E, additional, Linde, C, additional, Penicka, M, additional, Donal, E, additional, Voigt, J-U, additional, Smiseth, OA, additional, and Hopp, E, additional

Published
2022
Full Text
View/download PDF

33. Contributors

Author

Anagnostopoulos, C.D., primary, Badano, L.P., additional, Baksi, A.J., additional, Bekkers, S.C.A.M., additional, Bischoff, B., additional, Bissell, M.M., additional, Braun, D., additional, Budde, R.P.J., additional, Buechel, R.R., additional, Camilleri, S., additional, Cappeliez, O., additional, Chow, B.J.W., additional, Coenen, A., additional, Cosyns, B., additional, Crean, A.M., additional, Dijkshoorn, M., additional, Donal, E., additional, Edvardsen, T., additional, Fernández-Golfín, C., additional, Ferreira, V.M., additional, Flotats, A., additional, Gaemperli, O., additional, Galderisi, M., additional, Galli, E., additional, Gaubert, J.-Y., additional, Gerber, B.L., additional, Gimelli, A., additional, Goetschalckx, K., additional, Greenwood, J.P., additional, Gurunathan, S., additional, Habets, J., additional, Habib, G., additional, Hasselberg, N.E., additional, Hausleiter, J., additional, Karamitsos, T.D., additional, Kaufmann, P.A., additional, Kietselaer, B.L., additional, Knaapen, P., additional, Lancellotti, P., additional, Lederlin, M., additional, Leeson, P., additional, Leiner, T., additional, Lombardi, M., additional, Lubberink, M., additional, Ludman, A.J., additional, Magalhães, T.A., additional, Mahjoub, H., additional, Mahnken, A., additional, Manrique, A., additional, Marra, M.P., additional, Motwani, M., additional, Muraru, D., additional, Neubauer, S., additional, Nieman, K., additional, Paelinck, B., additional, Pasquet, A.A., additional, Pennell, D.J., additional, Petersen, S.E., additional, Pibarot, P., additional, Pison, L., additional, Plein, S., additional, Polsani, V., additional, Premaratne, M., additional, Pugliese, F., additional, Rademakers, F.E., additional, Robson, M.D., additional, Rochitte, C.E., additional, Salgado, R., additional, Schulz-Menger, J., additional, Senior, R., additional, Singh, P., additional, Tawakol, A., additional, Tyler, D.J., additional, Vannan, M., additional, Wassmuth, R., additional, Zamorano, J., additional, and Zhou, X., additional

Published
2015
Full Text
View/download PDF

35. [Ambulatory management of bilateral secondary spontaneous pneumothorax in palliative care]

Author

Chauvin, P, Sohier, L, Rochas, Y, Kerjouan, M, Salé, A, Lederlin, M, Jouneau, S, CHU Pontchaillou [Rennes], Groupe Hospitalier Bretagne Sud (GHBS), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio], Soins ambulatoires, Pneumothorax, Pneumothorax spontané, Middle Aged, Metastases, Treatment Outcome, Chest tubes, Outpatient care, Drains thoraciques, Ambulatory Care, Palliative care, Soins palliatifs, Humans, Female, Spontaneous pneumothorax, Neoplasm Recurrence, Local, Métastases, Retrospective Studies
Abstract

National audience; INTRODUCTION: Secondary spontaneous pneumothoraces account for 35% of all pneumothoraces after the age of 50. Their management is still debated and can be challenging due to the underlying respiratory condition. In our observation, the use of small-bore chest tubes allowed prolonged ambulatory care in a palliative setting. CASE REPORT: We report the case of a 54-year-old woman suffering from a leiomyosarcoma with multiple pulmonary metastases who had repeated episodes of pneumothorax, one of which was bilateral. Treatment involved the bilateral insertion of 8.5F pigtail catheters connected to Heimlich valves that allowed management as an outpatient. Recurrences were treated similarly, in association with oncological management, providing great additional benefits for patient comfort in this palliative context. CONCLUSION: Altogether, this case report confirms the applicability of outpatient management for drained spontaneous secondary pneumothoraces, even bilateral, especially in a palliative-care setting.

Published
2021
Full Text
View/download PDF

39. Septal scar predicts non-response to cardiac resynchronization therapy

Author

Kjellstad Larsen, C, primary, Duchenne, J, additional, Galli, E, additional, Aalen, JM, additional, Bogaert, J, additional, Lederlin, M, additional, Kongsgaard, E, additional, Linde, C, additional, Penicka, M, additional, Donal, E, additional, Voigt, J-U, additional, Smiseth, OA, additional, and Hopp, E, additional

Published
2021
Full Text
View/download PDF

45. Le méthotrexate n’est pas associé à l’aggravation scanographique de la pneumopathie interstitielle diffuse associée à la polyarthrite rhumatoïde

Author

Tremblay, A., primary, Lucas, C., additional, Lapotre, T., additional, Cren, J.B., additional, Bouvard, B., additional, Herbette, M., additional, Saraux, A., additional, David, C., additional, Horusitzky, A., additional, Joffres, L., additional, Solau Gervais, E., additional, Le Noach, J., additional, Martin, A., additional, Salliot, C., additional, Lederlin, M., additional, Jouneau, S., additional, and Perdriger, A., additional

Published
2020
Full Text
View/download PDF

47. Clinical Outcomes at 1 Year in Patients with Idiopathic Pulmonary Fibrosis (IPF) Stratified by Annualized Weight Loss and Baseline Body Mass Index (BMI): A Post-Hoc Analysis from Ascend, Capacity, Inspire, and Riff

Author

Jouneau, S., primary, Crestani, B., additional, Thibault, R., additional, Lederlin, M., additional, Vernhet, L., additional, Yang, M., additional, Morgenthien, E., additional, Kirchgaessler, K.-U., additional, and Cottin, V., additional

Published
2020
Full Text
View/download PDF

48. La dénutrition est associée à une évolution clinique péjorative des patients avec fibrose pulmonaire idiopathique (FPI) : étude observationnelle longitudinale dans un centre de référence

Author

Jouneau, S., primary, Rousseau, C., additional, Lederlin, M., additional, Kerjouan, M., additional, Salé, A., additional, Guy, T., additional, Sohier, L., additional, Guillot, S., additional, Vernhet, L., additional, Oger, E., additional, and Thibault, R., additional

Published
2020
Full Text
View/download PDF

50. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

Author

Jouneau, S. (Stéphane), Crestani, B. (Bruno), Thibault, R. (Ronan), Lederlin, M. (Mathieu), Vernhet, L. (Laurent), Valenzuela, C. (Claudia), Wijsenbeek-Lourens, M.S. (Marlies), Kreuter, M. (Michael), Stansen, W. (Wibke), Quaresma, M. (Manuel), Cottin, V. (Vincent), Jouneau, S. (Stéphane), Crestani, B. (Bruno), Thibault, R. (Ronan), Lederlin, M. (Mathieu), Vernhet, L. (Laurent), Valenzuela, C. (Claudia), Wijsenbeek-Lourens, M.S. (Marlies), Kreuter, M. (Michael), Stansen, W. (Wibke), Quaresma, M. (Manuel), and Cottin, V. (Vincent)

Abstract

Background: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI at baseline or weight loss over 52 weeks was associated with FVC decline, or influenced the effect of nintedanib, in patients with IPF. Methods: Using pooled data from the two INPULSIS trials, we analysed the rate of decline in FVC (mL/yr) over 52 weeks in patients treated with nintedanib and placebo in subgroups by baseline BMI (< 25; ≥25 to < 30; ≥30 kg/m2) and by weight loss over 52 weeks (≤5; > 5%) using random coefficient regression. Results: In the placebo group, the mean rate of FVC decline over 52 weeks was numerically greater in patients with lower baseline BMI (− 283.3 [SE 22.4], − 207.9 [20.9] and − 104.5 [21.4] in patients with BMI < 25 kg/m2, ≥25 to < 30 kg/m2 and ≥ 30 kg/m2, respectively). Nintedanib reduced the rate of FVC decline versus placebo in all subgroups by BMI, with a consistent treatment effect across subgroups (interaction p = 0.31). In the placebo group, the mean rate of FVC decline was numerically greater in patients with > 5% than ≤5% weight loss over 52 weeks (− 312.7 [SE 32.2] versus − 199.5 [SE 14.4] mL/year). Nintedanib reduced the rate of FVC decline versus placebo in both subgroups by weight loss, with a greater treatment effect in patients with > 5% weight loss (interaction p = 0.0008). The adverse event profile of nintedanib was similar across subgroups. Conclusions: In patients with IPF, lower BMI and weight loss may be associated with faster decline in FVC. Nintedanib reduces the rate of FVC decline both in patients who lose weight on treatment and those who do not. Trial registration: ClinicalTrials.gov; Nos. NCT01335464 and NCT01335477; URL: www.clinicaltrials.gov.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results